Koers Respirerx Pharmaceuticals Inc Other OTC
Aandelen
US2205243007
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 289K 268K |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -3 mln. -2,79 mln. | Nettowinst (verlies) 2022 | -2 mln. -1,86 mln. | EV/omzet 2021 | - |
Nettoschuld 2021 | 2,08 mln. 1,93 mln. | Nettoschuld 2022 | 2,71 mln. 2,52 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-0,29
x | K/w-verhouding 2022 |
-0,06
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 93,37% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22-03-13 |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22-03-13 |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 15-10-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22-03-13 |
Director/Board Member | - | 22-03-23 | |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22-03-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |
- Beurs
- Aandelen
- Koers RSPI
- Koers